ADORA2A and cancer: In recent years, the immunosuppressive role of the CD73/A2AR axis in cancer has been investigated (47, 48), and the results suggest it may represent another attractive target complementing PD-1/PD-L1 and CTLA-4 blockade for antitumor immunotherapy (49–51).